全身应用抗血栓药物在口腔手术出血风险中的研究进展  

Progress on systemic application of antithrombotic drugs in the bleeding risk during oral surgery

作　　者：赵少剑 王乳威 王其宝[2] ZHAO Shaojian;WANG Ruwei;WANG Qibao(Binzhou Medical University,Yantai,Shandong 264003,China;Jinan Stomatological Hospital,Jinan,Shandong 250001,China)

机构地区：[1]滨州医学院,山东烟台264003 [2]济南市口腔医院,山东济南250001

出　　处：《医药前沿》2023年第1期43-45,共3页Journal of Frontiers of Medicine

基　　金：济南市卫生健康委员会科技计划项目(2022-2-168)。

摘　　要：血栓性疾病是由于血栓形成后血流受阻,或栓子脱落导致下游血流中断,造成组织器官的缺血和坏死。目前临床上主要使用抗血小板药物和抗凝药物来预防和治疗动静脉血栓。由于患牙拔除术、牙周手术、显微根尖手术以及种植手术等会对软组织及骨组织造成一定程度的创伤,因此血液性疾病的患者(例如凝血功能异常)进行口腔手术具有一定的挑战性,甚至无法进行手术。本文就全身服用抗血栓药物的患者在口腔手术时的出血风险研究进展进行综述。Thrombotic diseases are caused by the blockage of blood flow after the formation of thrombus,or the loss of emboli leads to the interruption of downstream blood flow,resulting in ischemia and necrosis of tissues and organs.At present,antiplatelet and anticoagulant drugs are mainly used to prevent and treat arteriovenous thrombosis.Because tooth extraction,endodontic microsurgery,periodontal surgery and implant surgery can cause certain degree of trauma to soft tissue and bone tissue;oral surgery for patients with hematological diseases(such as abnormal blood coagulation)is challenging,and even impossible to perform surgery.This paper discusses the bleeding risk of patients with systemic application of antithrombotic drugs during oral surgery.

关 键 词：抗血栓药物 抗血小板药物 抗凝药物 口腔手术 出血风险 综述 

分 类 号：R61[医药卫生—外科学]